CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $) In Millions	9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010
Cash Flows From Operating Activities:
Net Earnings	$ 4,029	$ 3,671
Adjustments to reconcile net earnings to net cash provided by operating activities:
Net earnings attributable to noncontrolling interest	(1,172)	(1,052)
Depreciation	333	348
Amortization	261	198
Impairment charges	28	207
Deferred income tax expense	273	100
Stock-based compensation expense	120	143
Other adjustments	(138)	(34)
Changes in operating assets and liabilities:
Receivables	(152)	(122)
Inventories	(150)	(37)
Accounts payable	309	77
Deferred income	(119)	1
U.S. and foreign income taxes payable	(20)	(187)
Other	(330)	(417)
Net Cash Provided by Operating Activities	3,272	2,896
Cash Flows From Investing Activities:
Proceeds from sale and maturities of marketable securities	3,808	2,612
Purchases of marketable securities	(5,344)	(3,703)
Additions to property, plant and equipment and capitalized software	(233)	(299)
Proceeds from sale of businesses and other investing activities		57
Proceeds from sale of businesses and other investing activities	147
Purchase of Amira Pharmaceuticals, Inc., net of cash acquired	(310)
Net Cash Used in Investing Activities	(1,932)	(1,333)
Cash Flows From Financing Activities:
Short-term borrowings/(repayments)	67	54
Long-term debt borrowings		6
Long-term debt repayments	(78)	(42)
Interest rate swap terminations	296	98
Issuances of common stock	365	211
Common stock repurchases	(859)	(353)
Dividends paid	(1,694)	(1,653)
Net Cash Used in Financing Activities	(1,903)	(1,679)
Effect of Exchange Rates on Cash and Cash Equivalents	1	14
(Decrease)/Increase in Cash and Cash Equivalents	(562)	(102)
Cash and Cash Equivalents at Beginning of Period	5,033	7,683
Cash and Cash Equivalents at End of Period	$ 4,471	$ 7,581